Strong Q3 revenue growth of 12% YoY, raised fiscal 2026 revenue guidance to $35 billion (17% growth), consistent earnings history with 74.9% EPS Linearity, and growing exposure to high-growth AI infrastructure markets support positive outlook.
Strong AI infrastructure growth trajectory with $13.6B projected AI revenue for 2026, strategic facility expansions in India and Malaysia, solid earnings surprise history, favorable valuation discount relative to industry peers, and Zacks Rank #2 rating support positive outlook despite near-term headwinds.
While Jabil shows positive fundamentals with strong projected earnings growth (23.1% YoY for upcoming quarter, 30.67% for full year) and attractive valuation metrics (trading below industry P/E average with low PEG ratio of 0.63), the Zacks Rank #3 (Hold) rating and stagnant EPS estimates over the past 30 days suggest limited near-term upside momentum, warranting a neutral stance.
JBL is positioned as the better investment with expected 30.7% EPS growth in 2026, stable earnings estimates over the past 60 days, attractive valuation (0.75 forward sales), strong operational execution, global presence across 100 locations in 30 countries, and exposure to growing markets like AI data centers and 5G infrastructure.
While the stock declined 2.75% and has lost 14.96% over the past month, the company shows strong fundamental growth prospects with expected EPS growth of 23.1% and revenue growth of 16.51% for the upcoming quarter. The Zacks Rank #3 (Hold) rating and valuation discount relative to industry peers suggest a balanced outlook, neither strongly bullish nor bearish.
Strong Q3 revenue growth of 12% YoY to $8.8B with improved core margins at 5.8%. Diversified global footprint across 25 countries provides competitive advantage in navigating geopolitical and tariff uncertainties. Strategic capacity expansions underway to support future demand.
Strong AI-driven revenue growth trajectory ($9B to $13.6B), outperformance vs. industry (36.2% vs 23.6%), diverse portfolio across healthcare and renewable energy, and strategic capacity expansions support positive outlook.
While Jabil showed positive daily performance (+1.26%) and strong expected earnings growth (23.1% YoY), the stock has underperformed over the past month (-4.32%) and holds a Zacks Rank #3 (Hold) rating. The Forward P/E of 23.66 is below industry average, suggesting fair valuation, but the hold rating and recent underperformance relative to sector gains (7.52%) warrant a neutral stance.
Strong Q2 results with 23% revenue growth and 39% earnings growth; raised full-year guidance with 46% AI revenue growth expected; expanding capacity and securing new hyperscaler customers; analyst consensus suggests 53% upside potential to $379 per share by fiscal 2028; trading at reasonable 20x forward earnings multiple
Articles that tag JBL but are mainly about other companies.
Identified as a key competitor with broad HealthTech business and strong manufacturing capabilities, but no specific performance metrics or outlook provided in the article.
Company expects adjusted free cash flow above $1.4 billion in fiscal 2026, exceeding prior guidance. Strong cash generation, expanding margins, and efficient capital spending demonstrate solid financial health and operational execution.
Major EMS provider with presence in Malaysia's market, well-positioned to capture growth from expanding semiconductor, consumer electronics, and advanced packaging demand.
Jabil is mentioned as an upcoming earnings reporter with expected strong growth (EPS up 23.1% YoY and revenues up 16.5% YoY). However, no actual results or rating has been provided, making sentiment assessment premature.
Listed as a leading market player and mentioned as expanding manufacturing capacities in North America to meet growing telecom OEM demands, benefiting from the market's projected growth.
Company is experiencing accelerating AI-driven growth with 51% YoY increase in AI revenue, expanding customer base including hyperscalers, consistent guidance raises, and attractive valuation (1.2x sales) offering significant upside potential to 3x sales by 2028.
Strong revenue growth (23% YoY), impressive earnings growth (38% YoY), anticipated 46% AI revenue increase, potential addition of third hyperscaler customer, and booming AI server market demand support bullish outlook for upcoming earnings report.
Acquisition of Pharmaceutics International Inc. in February 2025 strengthens capabilities in aseptic filling, lyophilization, and oral solid dose production, enhancing market position.
Jabil is highlighted as a leading CDMO player and specifically mentioned for its January 2026 partnership with TxSphere for complex drug-device products, demonstrating market leadership and strategic growth initiatives.
Strong AI revenue growth (35% increase to $12.1B), exceeded earnings expectations in last four quarters, expanding hyperscaler customer base, ahead-of-schedule facility retrofitting, attractive forward P/E ratio of 22, and potential for further guidance raises.
AI is now primary growth driver with 35% AI revenue growth guidance to $12.1 billion for fiscal 2026. Company investing $500 million in AI manufacturing capacity expansion. Trading at 19x forward earnings with discount to Nasdaq-100. AI server market forecast to grow 34% annually through 2030.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
